Prokineticin 1 receptor

Details for Australian Patent Application No. 2006227394 (hide)

Owner Janssen Pharmaceutica N.V.

Inventors Hornby, Pamela; Wade, Paul; Prouty, Stephen M.; Palmer, Jeffrey M.; Mabus, John R.

Agent Shelston IP

Pub. Number AU-A-2006227394

PCT Pub. Number WO2006/102112

Priority 60/665,002 24.03.05 US; 60/731,421 28.10.05 US

Filing date 15 March 2006

Wipo publication date 28 September 2006

International Classifications

A61K 31/513 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 1/12 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

18 October 2007 PCT application entered the National Phase

  PCT publication WO2006/102112 Priority application(s): WO2006/102112

25 February 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006227399-Nanoparticulate biphosphonate compositions

2006227393-Biomarker for sensitivity to mTOR inhibitor therapy in kidney cancer